Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Brand Name : Tirofiban Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2023
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tirofiban,Clopidogrel,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...
Brand Name : Aggrastat
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2020
Lead Product(s) : Tirofiban,Clopidogrel,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Brand Name : Aggrastat
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2020
Lead Product(s) : Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $3.0 million
March 10, 2020
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?